Mobilized peripheral blood has almost completely replaced marrow as a source of hematopoietic stem cells for autologous transplantation. The faster hematopoietic recovery that results from use of this product has contributed to the decrease in the morbidity and mortality of transplant and has led to a wider use of the therapy, including treatment of older patients. Because of these encouraging results, phase II studies were initiated to explore the feasibility of using allogeneic peripheral blood stem cells (PBSC) instead of marrow in the allogeneic stem cell transplantation setting.
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1,2 Most studies to date have shown faster neutrophil and platelet recovery, mimicking the data obtained in autologous transplant studies.
One major concern of this approach was the possibility of increasing the incidence of acute graft-versus-host disease (GVHD) due to the infusion of a large number of T cells with the peripheral blood stem cell product. To the surprise of many investigators, the use of PBSC does not appear to increase the rate of severe acute GVHD compared to marrow, although most studies do suggest that the incidence of chronic GVHD is increased. [1] [2] [3] In order to further address the long-term effect on complications and outcome associated with the use of peripheral blood compared to marrow, a prospective randomized phase III study was initiated by investigators at the Fred Hutchinson Cancer Research Center, City of Hope National Medical Center, and Stanford University Hospital. Patients who were entered on trial were stratified for age and disease stage. The median age for both groups was 42 and the distribution of favorable vs advanced disease was equal in both treatment groups. The combination of methotrexate (+1, +3, +6, +11) and cyclosporine was used as GVHD prophylaxis in all patients in this study. The preparative regimens varied depending upon the disease; most patients with chronic myelogenous leukemia (CML) received a busulfan/ cyclophosphamide regimen, while those patients with acute myelogenous leukemia (AML) or other advanced diseases received a TBI-based regimen. Neutrophil engraftment occurred at day 21 in the group of patients receiving marrow compared to day 15 in the peripheral blood patient group (P = 0.0001); platelet engraftment similarly was earlier in the peripheral blood group (P = 0.0008). Severe acute GVHD (II-IV) was the same (13% vs 16%) in both groups (P = 0.56) and the rate of chronic GVHD was 28% for bone marrow and 38% for peripheral blood (P = 0.94). 4 In terms of outcome, there was an overall greater probability of death among the recipients of marrow (P Ͻ 0.02). Patients with either CML in chronic phase or AML in first remission had very good survival in both arms. The biggest impact on outcome with the use of peripheral blood was seen in those patients who had a poor prognosis, ie those with advanced disease at the time of transplant. These patients had improved survival with peripheral blood compared to marrow (P Ͻ 0.04) with a decrease in regimen-related toxicity, infection, and relapse. 4 There are several potential explanations for why the use of PBSC may not be associated with a higher incidence of GVHD. Given murine data demonstrating a dose response relationship between the number of T cells infused and the amount of GVHD, it may be that there is a threshold in humans of infused T cells beyond which no further GVHD will occur. Another factor may be that patients recover their blood counts faster after peripheral blood transplant, thus decreasing the risk of infection and other complications that might have an impact on GVHD, including the ability to utilize adequate doses of immunosuppression. The composition of the graft may also influence GVHD if, in fact, more TH2, or cytotoxic CD4 + cells, are reinfused. In addition, the presence of dendritic cells from GCSF mobilization and their effect on GVHD has not been fully evaluated.
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The pattern and rate of T cell immune reconstitution has been studied with respect to cytomegalovirus (CMV)-specific cells following PBSC transplant. Since at least one log more T cells are reinfused with the stem cell product, it was hypothesized that there may be enough CMV-specific cells infused such that reactivation of virus could be prevented after transplant. At the City of Hope, we studied 43 patients who had received a PBSC transplant, 35 of whom were seropositive and therefore would be expected to reactivate CMV. Eight other patients who were seronegative had donors who were seropositive. All patients had received a radiation therapybased transplant regimen, cyclosporine, and methotrexate for GVHD prophylaxis and all were screened twice a week for viral reactivation for the first 100 days using shell vial culture for CMV. Of the 35 patients with positive serology and who received peripheral blood, 21 reactivated cytomegalovirus. Of those seronegative patients who had a positive donor, two reactivated. This rate of CMV reactivation is similar to what we have observed in patients who received marrow and who were seropositive at the time of transplant. The median time of this reactivation was 47 days, which is also similar to what is seen in marrow transplants. Thus, despite the large infusion of T cells, CMV reactivation after peripheral stem cell reinfusion was similar to what is observed after marrow transplant, and suggests that screening and intervention strategies should be the same for patients receiving either PBSC or marrow products.
The question of the impact on relapse following PBSC has also been explored. A recent study in CML patients suggested that PBSC transplantation was associated with a decrease in PCR-positive relapse compared to marrow. 8 Cytogenetic relapse was also decreased in those patients who received a peripheral blood graft. No firm conclusions can yet be drawn, as there were a significant number of mismatched donors in the study, suggesting that a more potent graft-versus-leukemia effect may have contributed to the decrease in relapse rate. Further prospective studies are indicated to compare the longterm results of marrow vs peripheral blood products on relapse of disease in patients transplanted for a similar disease, using a common preparative regimen and GVHD prophylaxis. 9 In summary, the long-term effects of allogeneic stem cell transplant with respect to chronic GVHD and relapse have not yet been completely resolved. Even if the short-term benefit is conclusive, the impact of chronic GVHD on a patient's longterm well-being, as well as on the disease recurrence, must be carefully assessed. As the data to date indicate more of a benefit on poor risk patients, additional studies will be necessary to determine the overall benefit in those patients with better risk disease.
